Literature DB >> 18479385

Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disability.

Christopher P Derry1, Sarah E Heron, Fiona Phillips, Stephen Howell, Jacinta MacMahon, Hilary A Phillips, John S Duncan, John C Mulley, Samuel F Berkovic, Ingrid E Scheffer.   

Abstract

Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a relatively benign epilepsy syndrome with few comorbidities. Here we describe two families with unusually severe ADNFLE, with associated psychiatric, behavioral, and cognitive features. Detailed clinical data on 17 affected individuals were obtained, and genotyping of microsatellite markers, linkage analysis, and sequencing of candidate genes was performed. The severe ADNFLE phenotype in these families was often refractory to treatment, with status epilepticus occurring in 24% of subjects. Psychiatric or behavioral disorders occurred in 53%, with intellectual disability in 24%, and developmental regression in two individuals. No mutations were identified in alpha4, alpha2, or beta2 nAChR subunits. In one family there was evidence of linkage to a region of 15q24 without nAChR subunit genes. In conclusion, severe ADNFLE has significant medical, psychiatric, and intellectual morbidity. The molecular basis of severe ADNFLE is unknown but may involve non-nAChR-related mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479385     DOI: 10.1111/j.1528-1167.2008.01652.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

Review 1.  The sleep manifestations of frontal lobe epilepsy.

Authors:  Christopher P Derry
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

2.  Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Sarah E Heron; Katherine R Smith; Melanie Bahlo; Lino Nobili; Esther Kahana; Laura Licchetta; Karen L Oliver; Aziz Mazarib; Zaid Afawi; Amos Korczyn; Giuseppe Plazzi; Steven Petrou; Samuel F Berkovic; Ingrid E Scheffer; Leanne M Dibbens
Journal:  Nat Genet       Date:  2012-10-21       Impact factor: 38.330

3.  Mutations in KCNT1 cause a spectrum of focal epilepsies.

Authors:  Rikke S Møller; Sarah E Heron; Line H G Larsen; Chiao Xin Lim; Michael G Ricos; Marta A Bayly; Marjan J A van Kempen; Sylvia Klinkenberg; Ian Andrews; Kent Kelley; Gabriel M Ronen; David Callen; Jacinta M McMahon; Simone C Yendle; Gemma L Carvill; Heather C Mefford; Rima Nabbout; Annapurna Poduri; Pasquale Striano; Maria G Baglietto; Federico Zara; Nicholas J Smith; Clair Pridmore; Elena Gardella; Marina Nikanorova; Hans Atli Dahl; Pia Gellert; Ingrid E Scheffer; Boudewijn Gunning; Bente Kragh-Olsen; Leanne M Dibbens
Journal:  Epilepsia       Date:  2015-06-30       Impact factor: 5.864

Review 4.  Genetic basis in epilepsies caused by malformations of cortical development and in those with structurally normal brain.

Authors:  Danielle M Andrade
Journal:  Hum Genet       Date:  2009-06-18       Impact factor: 4.132

5.  Quinidine in the treatment of KCNT1-positive epilepsies.

Authors:  Mohamad A Mikati; Yong-Hui Jiang; Michael Carboni; Vandana Shashi; Slave Petrovski; Rebecca Spillmann; Carol J Milligan; Melody Li; Annette Grefe; Allyn McConkie; Samuel Berkovic; Ingrid Scheffer; Saul Mullen; Melanie Bonner; Steven Petrou; David Goldstein
Journal:  Ann Neurol       Date:  2015-11-18       Impact factor: 10.422

6.  KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.

Authors:  Carol J Milligan; Melody Li; Elena V Gazina; Sarah E Heron; Umesh Nair; Chantel Trager; Christopher A Reid; Anu Venkat; Donald P Younkin; Dennis J Dlugos; Slavé Petrovski; David B Goldstein; Leanne M Dibbens; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou
Journal:  Ann Neurol       Date:  2014-04-14       Impact factor: 10.422

7.  Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series.

Authors:  Andrew M Griffin; Kristopher M Kahlig; Robert John Hatch; Zoë A Hughes; Mark L Chapman; Brett Antonio; Brian E Marron; Marion Wittmann; Gabriel Martinez-Botella
Journal:  ACS Med Chem Lett       Date:  2021-03-09       Impact factor: 4.345

8.  Altered activity-rest patterns in mice with a human autosomal-dominant nocturnal frontal lobe epilepsy mutation in the β2 nicotinic receptor.

Authors:  J Xu; B N Cohen; Y Zhu; G Dziewczapolski; S Panda; H A Lester; S F Heinemann; A Contractor
Journal:  Mol Psychiatry       Date:  2010-07-06       Impact factor: 15.992

9.  Major channels involved in neuropsychiatric disorders and therapeutic perspectives.

Authors:  Paola Imbrici; Diana Conte Camerino; Domenico Tricarico
Journal:  Front Genet       Date:  2013-05-07       Impact factor: 4.599

Review 10.  Patient considerations in the management of focal seizures in children and adolescents.

Authors:  Daniel Kenney; Elaine Wirrell
Journal:  Adolesc Health Med Ther       Date:  2014-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.